Medicare has launched a pilot program intended to make GLP-1 weight-loss drugs easier to get. Some seniors pay as little as $50 a month under the plan. But KFF Health News reports that many patients with the most serious illnesses do not qualify for the discount.
A discount with a catch
Coverage under the pilot follows a defined set of conditions and requirements rather than a simple prescription. Patients who fall outside those lines pay the retail price, which for drugs such as Zepbound can run to hundreds of dollars a month. KFF Health News profiled Jeff La Marca, who received a prescription for Zepbound in January but could not afford the $750 monthly cost. He is exactly the kind of patient the pilot was designed to help.
Why the rules are narrow
Medicare has long been barred from paying for drugs used for weight loss, so the program is a limited workaround rather than a full benefit. That constraint shapes every part of the design: which diagnoses count, which dose is covered and who signs off. The result, doctors say, is a patchwork in which two patients with similar body weight and similar health risks can face very different bills depending on which condition is listed first in a chart.
Demand keeps climbing
GLP-1 drugs including Wegovy, Zepbound, Ozempic and Mounjaro have been shown to drive weight loss and, in some patient groups, to cut the risk of heart attacks and other complications. Employers and private insurers have responded by tightening their own rules, adding prior authorisation steps and, in some cases, dropping coverage. For older patients on fixed incomes, the pilot is the difference between a manageable monthly payment and a bill they cannot meet.
Doctors following the programme say the next question is whether the criteria will widen once the pilot data is reviewed. Until then, patients are being told to check eligibility carefully before they fill a prescription, because the price at the counter depends on rules most of them never see.